FDA Approved: VIMIZIM — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VIMIZIM (elosulfase alfa) from BioMarin Pharmaceutical, updating its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morquio Syndrome Type
• Mucopolysaccharidosis Type Iva

Drugs mentioned

• VIMIZIM (Elosulfase alfa)

Snippet

SUPPL AP for VIMIZIM (ELOSULFASE ALFA)